<DOC>
	<DOCNO>NCT02134080</DOCNO>
	<brief_summary>The purpose trial examine safety , tolerability feasibility use FAAH inhibitor treatment adult Tourette syndrome .</brief_summary>
	<brief_title>FAAH Inhibitor Trial Adults With Tourette Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>Adult 1860 year age Meet DSM IV criterion diagnosis Tourette 's syndrome Significant current tic symptom : YGTSS total tic score great equal 22 baseline On stable psychiatric medication regimen minimum 4 week prior begin trial . Accepted method birth control Comorbid bipolar disorder , psychotic disorder , substance use disorder , developmental disorder intellectual disability ( IQ &lt; 70 ) . Current use medication significant effect cannabinoid dopamine system . Subjects specifically exclude recent use ( within last 8 week ) antipsychotic medication , dopamine agonist psychostimulants . Recent change ( less 4 week ) medication potential effect tic severity ( alpha2 agonist ( guanfacine , clonidine prazosin ) , SSRIs , clomipramine , naltrexone , lithium , anxiolytic , topiramate , baclofen etc. ) . Medication change define include dose change medication discontinuation . Recent change behavioral treatment Tourette syndrome comorbid condition ( i.e . OCD ) within last 4 week initiation behavioral therapy tic within last 12 week . Positive pregnancy test drug screen test History cannabis dependence Significant Medical Comorbidity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Tourette Syndrome</keyword>
	<keyword>FAAH-Inhibitor</keyword>
	<keyword>Tics</keyword>
	<keyword>Tic Disorders</keyword>
</DOC>